Fig. 3: Pathway of fragment-to-lead discovery and development.
From: WRN structural flexibility showcased through fragment-based lead discovery of inhibitors
WRN inhibitor structures evolved from fragments 1 and 2, highlighting inflection points in the exploration of the series’ structure–activity relationships, are presented at the top. Structures of fragments 3 and 4, for which no structure-based chemical expansion was performed, are displayed at the bottom.
